GxPChat

• Product Spotlight

One conversational AI interface connecting specialized agents for SOP drafting, audit readiness, CSV, and 21 CFR Part 11 compliance.

Try GxPChat →

Saram Insights

Thoughts and strategies on the intersection of Biotech, Artificial Intelligence, and Regulatory Compliance.

Two of Eighty-Six: The Validation Deficit in AI Biomarker Discovery

A 2025 review scoped 86 AI models for Alzheimer's digital biomarkers. Two had external validation. Three or four checked calibration. One acknowledged TRIPOD reporting. Separately, a 2021 review found 78% of omics-based stratification studies validated internally only. This is a provenance audit of AI precision medicine — including the regulatory path, which is narrower than most business plans assume.

Read Article →

Representation Is Solved, Simulation Isn't: Where AI Virtual Cells Actually Stand

Five single-cell foundation models and two deep learning models were benchmarked on the standard CRISPRa doubles task. All of them had higher prediction error than a deliberately trivial additive baseline, and none beat predicting no change. The rebuttal says the metrics are miscalibrated. Either way, evaluation design — not architecture — is the contested variable, and the field's own 2026 challenge goes zero-shot in November.

Read Article →